Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track ENVB with free AI briefings, catalyst countdowns, and dilution alerts.

ENVB · Enveric Biosciences, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$8.3M Cash on Hand
10.6mo Cash Runway
Follow ENVB by email Get an email when ENVB reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about ENVB, unsubscribe in one click. Privacy

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

💰 Cash Runway & Dilution Risk

ENVB holds $8.3M in cash and short-term investments (as of Jun 30, 2026) and burns about $2.4M/quarter from operations, an estimated runway of 10.6 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 70 · High

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ENVB files for a raise →

👥 Who Owns ENVB

Insiders 13.7% Other 5%+ holders 3.2% Institutions 16.4% Public and other holders 66.7%
HolderTypeShares% of sharesAs of
Armistice Capital, LLC Institution (13G, 5%+) 405,092 9.05% 2026-06-30
Sio Capital Management, LLC Institution (13G, 5%+) 330,000 7.37% 2026-09-30
Joseph Edward Tucker
Chief Executive Officer, Director
Insider 271,479 6.07% 2026-06-01
Kevin Michael Coveney
Chief Financial Officer
Insider 180,746 4.04% 2026-06-01
Lind Global Fund III LP 5%+ holder (13G) 141,265 3.16% 2026-01-28
Peter J. Facchini
Chief Innovation Officer
Insider 27,755 0.62% 2026-06-01
Frank Pasqualone
Director
Insider 26,423 0.59% 2026-06-01
George A. Kegler
Director
Insider 26,418 0.59% 2026-06-01
Marcus Schabacker
Director
Insider 26,418 0.59% 2026-06-01
Michael D Webb
Director
Insider 26,416 0.59% 2026-06-01
Sheila DeWitt
Director
Insider 26,306 0.59% 2026-06-01

Share count 4,475,884 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the largest 13F holders. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full ENVB picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ENVB and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.